Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting the major immune system regulator OX40L
* Sanofi continues to build in key presence in alliance with strategy to pursue best-in-class treatments in defined areas
Paris and Cambridge, UK – 11 January 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapy, acquired Sanofi Kymab for about $ 1.1 billion under the agreement. And to pay the premium. Up to $ 350 million on achievement of certain milestones.
The deal would result in Sanofi gaining full global authority over KY1005, a fully human monoclonal antibody with a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a variety of immune-mediated diseases and inflammatory disorders.
“The Kymab acquisition adds KY1005 to our dynamic pipeline, which is a potential first class treatment for a range of immune and inflammatory diseases. Novel mechanisms of action may provide treatment with available therapies with therapeutic responses, ” Said Paul Hudson, Sanofi’s chief executive officer. “We understand from our ongoing work in weakening immunological diseases how important it is to find the right treatment for every patient. We look forward to rapidly developing this investigational drug. “
” Agreement is a testament The commitment, drive and expertise of the entire Kymab team and we are delighted in order to obtain this Support from Sanofi, ” Jodi Simon Sturge, Chief Executive Officer, Kaymab. “Together its Important Global Resources, W.I believenofi Kymab is the right partner for the progress of the pipeline of products And the merger will speed up time Take itS for Our novel treatment Service Go to the patients. “
KY1005: Antibody promising for inflammatory disorders
In August 2020, Kymab announced that KY1005 studied both primary endpoints in a Phase 2a trial for patients with moderate to severe atopic dermatitis whose disease is insufficiently controlled with topical corticosteroids. KY1005 demonstrated treatment effects consistent with placebo across various key points, including eczema area and severity index (EASI) and additional objective diagnostic measures.
“This acquisition aligns with our strategy to target fundamentally important disease pathways. We believe that OX40L, a key immune regulator, has the ability to rebalance the immune system without suppressing it, providing a promising new approach to treat a range of immune-mediated diseases. is, ” John Reid, MD PhD, Global Head of Research and Development in Sanofi.
Kaymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently developing as monotherapy in early stage 1/2 and in combination with a PD-L-1. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities.
Under the terms of the transaction, Sanofi will acquire Kaimb for approximately $ 1.1 billion in advance of some milestones and upfront payments of up to $ 350 million.
Sanofi plans to finance the transaction with cash in hand. The termination of the transaction is subject to the expiration or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Reform Act 1976 and other customary closing conditions. Sanofi expects to complete the acquisition in the first half of 2021.
Weil, Gotshal & Manges LLP, is acting as Sanofi’s legal counsel. JPMorgan is acting as financial advisor to Kaymab and Goodwin plc is acting as its legal advisor.
Kaymab is a clinical-stage biopharmaceutical company developing a fully human monoclonal antibody therapy, collectively called IntelliSelect, with a focus on immune mediated diseases and immuno-oncology.®. Kymab’s IntelliSelect transgenic platforms contain a complete variety of human antibodies, making them the most comprehensive antibody platform available.
Selection from a wide variety of fully human antibodies assures the highest probability of finding drug candidates with the best-in-class characteristics most rapidly and efficiently.
For more information on Kimb please visit http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent disease with vaccines, provide innovative treatments to fight pain and reduce pain. We stand with people who are suffering from rare diseases and millions of long term long term conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions worldwide.
Sanofi, empowering life
|Sanofi Media Relations Contact
Tel .: +1 (908) 205 2572
Sanofi Investor Relations Paris
Sanofi Investor Relations North America
IR Main Line:
Kaymab Media UK
Mary-Jane Elliott / Sukena Virji / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
| Sanofi Forward-Looking Statements
This press release contains amended statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and contain estimates and projections regarding future financial results, events, operations, services, product development and efficiencies and their underlying assumptions, plans, objectives, intentions and expectations. Statements may be included and statements regarding future performance. Forward-looking statements are usually identified by the words “expect”, “anticipate”, “believe”, “intend”, “anticipate”, “plan”, “will” and so on. Although Sanofi’s management believes the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that further notice and statements are subject to various risks and uncertainties, many of which are difficult to predict. And is generally beyond Sanofi’s control. It can isolate actual results and development differently from those expressed or anticipated or anticipated by further notice and statements. These risks and uncertainties include, among other things, risks related to the proposed terms or Sanofi’s ability to complete the acquisition at the proposed time, including receipt of necessary regulatory approvals, other risks associated with executing business combination transactions, such as risk businesses. Will not be successfully integrated, such integration may be more difficult, time consuming or costly than expected, or that the expected benefits of the acquisition will not be realized in the development, commercialization or potential of new products in the market, including competition. Uncertainty inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as FDA or EMA, including decisions by such authorities regarding the approval of any drug, device, or biological application . Filed for any product candidates as well as decisions. NG labeling and other matters that may affect the availability or business potential of any product candidates, the absence of a guarantee that candidates for any product, if approved, Will be commercially successful, future approval and commercial success of therapeutic options, Sanofi’s ability to profit from external development opportunities and to complete related transactions and / or obtain regulatory approval, Sanofi and Kimab’s intellectual property and any Also related to pending or future litigation and the final outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic risks and market conditions, cost improvement initiatives and subsequent changes, and COVID-19 Will have an impact on Sanofi and Kaymab and their respective customers, suppliers, vendors, and other business partners, and the financial position of any one of them. As well as the entirety of Sanofi and Kaymab’s employees and the global economy. Any material effect of COVID-19 on any of the foregoing may adversely affect Sanofi and Kymab. This situation is rapidly changing and additional effects may arise in which cenophy and cymab are not currently aware and may exacerbate other risks previously identified. While the list of factors presented here is representative, no list should be considered a description of all potential risks, uncertainties or assumptions that may have an adverse effect on Sanofi’s consolidated financial position or results of operations. The foregoing factors must be read in the context of risk or cautionary statements in public filings with the US Securities and Exchange Commission (“SEC”) and AMFs and AMFs made by Sanofi, including those listed under “Risk Factors and”. Regarding Forward Looking Statements in relation to the warnings filed with the SEC in the Sanofi annual report on Form 20-F for the year ended December 31, 2019 and later in Form 6-KS. Forward Looking Statements speak only on the date that, as required by applicable law, Sanofi assumes no obligation to update or revise any forward-looking information or statement.